Manufacturing

BFS technology can help maintain sterility during the biologics manufacturing process.

A simplified downstream process can save time and costs but requires enabling technologies.

Technological developments in real-time supply chain operations provide biologics manufacturers with capabilities that go beyond supply chain visibility to tangibly address security and quality challenges.

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Forge Biologics will offer three grades of plasmid manufacturing services at its Columbus, Ohio, location.

PerkinElmer has unveiled a cell analysis solution to streamline cell and gene therapy research and manufacturing.

The dedicated solid-state research and development suite is designed to promote discovery of novel polymorph, salt, and cocrystal forms.

Lonza has expanded its HPAPI multipurpose suite for payload-linker manufacturing.

Boehringer Ingelheim will use Virtuosi to train employees at three aseptic sites across its network.

Civica is expanding in the greater Richmond-Petersburg region and investing $27.8 million in a new testing facility.

The White House hopes to expand US modern biotech manufacturing and reduce reliance on foreign sources of bioindustrial materials.

Manufacturing and processing challenges surrounding mRNA can be overcome in order to realize the true potential of a technology 30 years in the making.

Document integrity is critical in the provision of raw materials for cell and gene therapy manufacturing.

For cell and gene therapies to reach their full potential, changes in manufacturing must be explored.

MilliporeSigma’s €130 million (USD$132 million) investment is designed to increase manufacturing capacity of single-use assemblies.

Charles River Laboratories and Cure AP-4 will collaborate on gene therapy manufacturing for AP-4 hereditary spastic paraplegia.

Hovione has expanded its drug product offering with a new manufacturing line dedicated to continuous tableting.

The projected growth in the biosimilars market will require increased bulk mAb manufacturing.

Scaling up chromatography resins requires a thorough understanding of their intended use.

Product safety and security are paramount when it comes to container closures.

More than anything else MonkeyPox and COVID-19 have shown that we are interdependent, no matter what continent you call home.

Forecyte Bio and Cytiva will team up to accelerate the development and manufacturing of cell and gene therapies.

Thermo Fisher Scientific’s new 300,000 ft² facility, located in Plainville, Mass., will specialize in manufacturing viral vectors.

Watson-Marlow and Franz Ziel GmbH have launched a new integrated solution to fast-track cell, gene, and biological therapies.

Grand River Aseptic Manufacturing has completed phase II of its facility expansion with the installation of two new sterile filling lines.